Abstract

Proton Pump Inhibitor Homogenous Suspensions: A Compounding Solution to Pediatric Gastroesophageal Reflux Disease

Author(s): Corsini Lindsay, Williams LaVonn A

Issue: Mar/Apr 2011 - Volume 15, Number 2

Page(s): 124-128

Download in electronic PDF format for $75
  • Proton Pump Inhibitor Homogenous Suspensions: A Compounding Solution to Pediatric Gastroesophageal Reflux Disease Page 1
  • Proton Pump Inhibitor Homogenous Suspensions: A Compounding Solution to Pediatric Gastroesophageal Reflux Disease Page 2
  • Proton Pump Inhibitor Homogenous Suspensions: A Compounding Solution to Pediatric Gastroesophageal Reflux Disease Page 3
  • Proton Pump Inhibitor Homogenous Suspensions: A Compounding Solution to Pediatric Gastroesophageal Reflux Disease Page 4
  • Proton Pump Inhibitor Homogenous Suspensions: A Compounding Solution to Pediatric Gastroesophageal Reflux Disease Page 5

Abstract

In the pediatric patient, histamine2-receptor antagonists and/or proton pump inhibitors are recommended for effective therapy of gastroesophageal reflux disease. Proton pump inhibitors, a group of drugs whose main action is a pronounced and long-lasting reduction of gastric acid production, are more cost effective than histamine2-receptor antagonists because of long-term and enhanced treatment outcome. The compounding of proton pump inhibitors is an exacting procedure. Compounding pharmacists have the potential to provide optimal pharmacologic treatment of gastroesophageal reflux disease to a young population that requires special attention.

Related Keywords

  • gastroesophageal reflux disease
  • GERD
  • children
  • infants
  • proton pump inhibitors
  • formulations
  • lansoprazole
  • omeprazole
  • pantoprazole
  • oral liquid suspensions

Related Categories

  • FORMULATIONS
  • GASTROENTEROLOGY
  • PEDIATRICS

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Mar/Apr 2011
Pg. 124-128
Proton Pump Inhibitor Homogenous Suspensions: A Compounding Solution to Pediatric Gastroesophageal Reflux Disease
Author(s): Corsini Lindsay, Williams LaVonn A
Jul/Aug 2003
Pg. 288-291
Basics of Compounding for Raynaud's Disease
Author(s): Glasnapp Andrew
Jan/Feb 2019
Pg. 58
Omeprazole 1 mg/mL and 4 mg/mL in Humco Flavor Sweet Sugar-Free Oral Liquid
Author(s): Allen Loyd V Jr
Nov/Dec 2019
Pg. 504-510
Compatibility of Flavoring Agents in Compounding Extemporaneous Omeprazole Oral Liquid
Author(s): Chuong Monica, Taglieri Catherine A, Huang Szu Yu, Sariol Anthony, Kitigawa Reina, Barman Koushik, Mistry Amee, Harris Donna L, Kerr Stephen G
May/Jun 2010
Pg. 246
Lansoprazole 3-mg/mL Oral Suspension
Author(s): Allen Loyd V Jr
Sep/Oct 2006
Pg. 391
Pantoprazole Sodium 2-mg/mL Oral Liquid
Author(s): Allen Loyd V Jr
Mar/Apr 2020
Pg. 140-147
The Effect of Manufacturer on the Compounding of Omeprazole Suspensions and Their Stability Assessment
Author(s): Meissner Svenja, Bansal Mahima, Dela Cruz Paula Donamae, Hanning Sara, Svirskis Darren
May/Jun 2023
Pg. 250-255
Stability of Omeprazole Extemporaneous Oral Solution in Chopin Base
Author(s): Spennacchio Antonio, Lopedota Angela Assunta, la Forgia Flavia Maria, Fontana Sergio, Denora Nunzio, Lopalco Antonio
Jan/Feb 2001
Pg. 6-8
Pediatric Compounding: Coloring Outside the Lines
Author(s): Preckshot John
Sep/Oct 2006
Pg. 389
Omeprazole 2-mg/mL Oral Liquid
Author(s): Allen Loyd V Jr
Nov/Dec 2017
Pg. 500-512
To Flavor or Not to Flavor Extemporaneous Omeprazole Liquid
Author(s): Chuong Monica C, Taglieri Catherine A, Kerr Stephen G
May/Jun 2003
Pg. 188-191
Treating Canine Hepatic Disease
Author(s): Davidson Gigi S
Jan/Feb 2007
Pg. 74
Lansoprazole 3-mg/mL Oral Liquid
Author(s): Allen Loyd V Jr
Nov/Dec 2005
Pg. 423-431
Compounding for a Pediatric Hospital
Author(s): McElhiney Linda F
Sep/Oct 2022
Pg. 429
Lansoprazole 3-mg/mL in Ora-Blend Suspension
Author(s): Allen Loyd V Jr
Jul/Aug 2022
Pg. 293-296
Compounding for Juvenile Idiopathic Arthritis and Other Pediatric Rheumatic Diseases
Author(s): Harrington Amy, Williams LaVonn
Jan/Feb 2001
Pg. 9-12
Stability Issues for Compounding Extemporaneously Prepared Oral Formulations for Pediatric Patients
Author(s): Schotik Debora
May/Jun 2016
Pg. 247-249
Extended Stability of Morphine and Sildenafil for Oral Use in Infants and Young Children
Author(s): Nahata Milap C
Mar/Apr 2012
Pg. 164-166
Stability of Omeprazole in SyrSpend SF Alka (Reconstituted)
Author(s): Whaley Paul A, Voudrie Mark A II, Sorenson Bridget
Nov/Dec 2015
Pg. 521-524
Long-term Stability of Esomeprazole in 5% Dextrose Infusion Polyolefin Bags at 5°C ± 3°C after Microwave Freeze-thaw Treatment
Author(s): Hecq Jean-Daniel, Rolin Catherine, Godet Marie, Gillet Patricia, Jamart Jacques, Galanti Laurence M